Ocrelizumab SC Phase III
Research payments
$2,183,620
Through program year 2025, $2,183,620 in research payments was reported against Ocrelizumab SC Phase III, across 237 payments.
- Paid by (largest first)
- Genentech, Inc.; F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $361,738 | 55 |
| 2024 | Research | $399,166 | 58 |
| 2023 | Research | $1,062,175 | 88 |
| 2022 | Research | $328,040 | 34 |
| 2021 | Research | $32,500 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
5 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.